TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “company” or “MVMD“) MVMD MVMDF (FRA: 20MP), an early-stage biotech company focused on the implementation, licensing and resale of key technologies and formulations, announced today that Dr. Azhar Rana, the Company’s Chief Medical Officer (“CMO”), will transition to an advisory role effective February 1, 2023.

As announced in its press release dated November 29, 2022 (the “November 29 Press Release”), the Company has completed the transition from a research and development phase to a focus on commercialization. As a result, the Company is beginning to align its human capital decisions with a profit-driven business plan based on the three lines of business outlined in the November 29 PR and focused on recruiting experienced talent in those specific areas of human resources and animal health commercialization over the coming months.

dr Rana joined the company as CMO in August 2021 and during his tenure has made numerous contributions to the company’s progress toward its commercialization goals. dr Rana will continue to advise MVMD’s management as required pursuant to a consulting agreement.

“We are Dr. Rana for his contributions to MVMD and look forward to continuing to work together in his new advisory role as we move through this next phase focused on our key projects and technologies and revenue generation with a view to and focusing on our overarching goal of long-term shareholders value,” said Dennis Hancock, President & CEO of Mountain Valley MD.

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.

Mountain Valley MD is building a world-class organization focused on the implementation, licensing and resale of key technologies and formulations:

• patented Quicksome™ oral formulation and delivery technologies,
• patented Quicksol™ solubility formulation technology
• licensed reseller of Agrarius™, a novel agricultural plant that…